Regimmune Corp., of Tokyo, closed a series D financing of $9.2 million, with the round led by Japan Asia Investment Corp. and Nippon Venture Capital Corp. Additional new investors included Mizuho Capital, Nissei Insurance, KSP Inc. and Mitsui-Sumitomo Insurance. Existing investors SMBC Venture Capital Co. Ltd. and Mitsubishi UFJ Bank Capital also participated in the round. The company plans to use proceeds primarily to support early stage product development. Earlier this month, Regimmune initiated a phase II trial at six U.S. centers for its lead compound, RGI-2001, in graft vs. host disease. A phase I study indicated no safety concerns and showed preliminary signs of efficacy.